The utility of insulin glargine in the treatment of diabetes mellitus

Pharmacotherapy
Jeffrey StroupRobert A Hamilton

Abstract

To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year. Retrospective study. Private endocrinology practice. One hundred ninety-seven patients with diabetes mellitus who were first prescribed insulin glargine from May 2001-April 2002 and were evaluable after 1 year of therapy Patients received insulin glargine instead of NPH insulin or in addition to their oral drug therapy Patients with diabetes type 1 (receiving insulin therapy) or type 2 (receiving oral drug therapy only, a combination of oral drug therapy and insulin, or insulin only) who had been treated with insulin glargine for 1 year were evaluated. Overall, A1C values decreased significantly (p<0.001) by 0.53 +/- 1.4% from a baseline mean of 8.1 +/- 1.7%. In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0.001) 0.57 +/- 1.5% from baseline. The A1C decreased by 0.71 +/- 1.3% (p=0.0043) from baseline in 33 patients with type 2 diabetes who previously received oral agents only Thirty-five patients with type 1 diabetes demonstrated no significant change in A1C (-0.22 +/- 1.0%, ...Continue Reading

References

Aug 22, 1985·The New England Journal of Medicine·R S MecklenburgR L Nielsen
Mar 1, 1984·Diabetes Care·C BinderS Pramming
Jan 4, 1997·Lancet·A H Barnett, D R Owens
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
May 8, 2003·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·M Massi BenedettiM Ziemen
Jun 6, 2003·The New England Journal of Medicine·David M NathanUNKNOWN Epidemiology of Diabetes Interventions and Complications Research Group
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators

❮ Previous
Next ❯

Citations

Nov 24, 2006·American Journal of Therapeutics·Athena Philis-TsimikasChris Walker
Sep 23, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Tiffany N EricksonCynthia Brennan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.